Science

The cheapest high-evidence screening test is the one almost nobody discusses

Medically reviewed by Longevity Benchmark Editorial Last reviewed 2026-08-22

University of Cincinnati researchers found just 15% of eligible US adults had discussed lung cancer screening with a doctor. What that gap says about scans.

August 22, 2026 · Science · Cancer screening · Preventive testing

What the study found

Researchers at the University of Cincinnati Cancer Center analyzed the National Cancer Institute's Health Information National Trends Survey, which is designed as a representative sample of adults across the United States, and reported that only 15% of eligible American adults had discussed lung cancer screening with their doctors. The work was published in the American Journal of Surgery, with Robert Van Haren, MD, associate professor of clinical surgery at the UC College of Medicine, as senior author and Sofia W. Viana as first author. Van Haren notes the 15% figure is an increase over prior HINTS data, and sets it against colonoscopy and mammography, which he describes as usually in the 70% to 80% range. The researchers hypothesize that stigma, fear around lung cancer, and the relative newness of the screening method are suppressing these conversations.

The short version

Among readers of a site like this one, the money flows in almost exactly the wrong order. A whole-body MRI or a multi-cancer blood test gets bought first, out of pocket, on evidence that is still maturing. Low-dose CT for lung cancer — a targeted screen carrying a USPSTF grade B recommendation, with defined eligibility criteria and an established harms profile — goes undiscussed by 85% of the people who qualify for it. If you meet the criteria, the highest-value screening conversation available to you is almost certainly the one you have not had. That conversation belongs with a clinician, and this is a survey about conversations, not a study showing anyone was harmed by missing one.

What it means for you

The useful frame here is sequencing. This site exists because people are willing to spend their own money on testing, and the questions we get are usually about which elective scan or panel to buy. This study is a reminder that the elective tier is the second question. The US Preventive Services Task Force recommends annual low-dose CT screening for adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years, at grade B. A grade B recommendation is a formal judgment that the benefit outweighs the harms in that specific population — a standard none of the self-pay whole-body scans currently meets. If you fall inside those criteria, raising it at your next appointment is a higher-yield use of ten minutes than any comparison table on this site.

That is not a reason to dismiss the elective tier, and it is not a claim that you personally qualify — only a clinician who knows your smoking history and your overall health can determine that. It is a reason to be honest about what you are buying when you buy it. Our full-body MRI guide and our reviews of Prenuvo and Ezra describe scans that look broadly in people without a defined risk profile, which is a genuinely different exercise from screening a high-risk group for one cancer with a test studied in that group. The same distinction applies to Galleri, whose manufacturer states it should be used in addition to routine screening a healthcare provider recommends — not instead of it. A negative whole-body MRI does not substitute for a lung CT you were eligible for, and neither does a blood test.

Note also what the screening conversation contains that a self-pay scan usually does not: a stopping rule and a stated harms profile. The Task Force says screening should be discontinued once a person has not smoked for 15 years, or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. That is a recommendation that tells you when to stop testing. Elective scanning markets rarely produce those, because the incentive runs the other way. When you are comparing what to spend on, weigh whether anyone in the process is empowered to tell you a test is not worth repeating.

What this survey cannot tell you

This is cross-sectional, self-reported survey data about whether a conversation happened. It does not measure whether people were scanned, whether scanning was appropriate for them, or what happened to anyone's health as a result — and a discussion rate is not an outcome. The sources available to us did not state the analytic sample size, so we are not reporting one. Rates of discussion also vary by region: the authors note that in the Greater Cincinnati area, nine of ten counties served by the Cancer Center exceed national smoking rates. Do not read the 15% as a statement about your own risk, and do not read a comparison with colonoscopy rates as evidence that one test is better than another. They screen for different cancers in different populations.

How this fits what we already know

We covered a companion finding on the other side of this ledger last week: a large Swedish cohort quantifying the mortality reduction associated with participating in colorectal screening, in our briefing on that study. Read together, the two describe a consistent pattern. The established, guideline-backed screening programs are where the strongest outcome evidence lives, and the gap between what they could deliver and what people actually take up remains wide — 85% of eligible adults not having had the lung screening conversation is a large amount of available benefit sitting unused. The newer, broader, self-pay tests we benchmark across the platform hub are not competitors to that, whatever the marketing implies. They are an additional, less-proven layer, and the case for buying one is strongest for people who have already settled the recommended screenings that apply to them with a clinician.

Sources

University of Cincinnati, "Too few eligible adults discuss low-dose CT lung screening: UC study," August 2026, uc.edu (accessed August 22, 2026).
Viana SW, et al., American Journal of Surgery, 2026. DOI 10.1016/j.amjsurg.2026.117131.
Medical Xpress, "Study shows lack of awareness for lung cancer screenings across country," August 21, 2026, medicalxpress.com (accessed August 22, 2026).
US Preventive Services Task Force, "Lung Cancer: Screening" (grade B recommendation, eligibility criteria and harms), uspreventiveservicestaskforce.org (accessed August 22, 2026).

Frequently Asked Questions

What does the 15% figure actually measure?

It measures conversation, not scanning. University of Cincinnati researchers analyzed the National Cancer Institute's Health Information National Trends Survey and reported that 15% of eligible American adults had discussed lung cancer screening with a doctor. That is self-reported survey data from a sample designed to represent US adults, so it captures whether the subject came up — not whether anyone was scanned, and not whether a scan was appropriate for them.

Who does the USPSTF say is eligible for lung cancer screening?

The US Preventive Services Task Force gives a grade B recommendation for annual low-dose CT screening in adults aged 50 to 80 who have a 20 pack-year smoking history and who currently smoke or quit within the past 15 years. It states screening should stop once a person has not smoked for 15 years, or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. Whether you meet those criteria is a determination for your clinician, not a checkout page.

Is a low-dose CT the same thing as a full-body MRI scan?

No. They are different tests, aimed at different questions, with different evidence behind them. Low-dose CT for lung cancer is a targeted screen in a defined high-risk group and carries a USPSTF grade B recommendation. A self-pay whole-body MRI scans broadly in people without a defined risk profile and has no such recommendation. Our full-body MRI guide covers what that distinction means for a buyer.

Does low-dose CT screening have downsides?

Yes, and the USPSTF lists them. False-positive results can lead to unnecessary tests and invasive procedures. Incidental findings ranged from 4.4% to 40.7% across the evidence reviewed, including coronary artery calcification and various nodules. Radiation exposure was estimated at 0.65 to 2.36 mSv per scan. Modeling studies put overdiagnosis at about 6.0% of lung cancers detected. The Task Force still recommends screening for the eligible group, which is what a grade B means — a judgment that benefits outweigh these harms in that population specifically.

I have never smoked. Is this relevant to me?

Not directly — the eligibility criteria are built on smoking history, and the recommendation does not extend to never-smokers. The transferable lesson is about sequencing: the screening tests with randomized evidence and formal recommendations behind them are usually the ones to settle with a clinician before adding elective self-pay scans. Which of those apply to you depends on your age, sex, family history and other risk factors.